Cervical CancerNCT07385976
The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients
An observational study of Cervical Cancer and Cervical Intraepithelial Neoplasm, run by Far Eastern Memorial Hospital at 2 sites in Taiwan.
Trial summary
This study will elucidate the role of 3D transvaginal ultrasound in assessing (1) cervical vascularity and blood flow in patients with cervical cancer and cervical intraepithelial neoplasm, and (2) tumor vascularity and blood flow in patients with ovarian cancer. Read more about this study
- Who is it for?
- Any age, women onlyHealthy volunteers can take part
- Conditions the study is for
- Cervical Cancer, Cervical Intraepithelial Neoplasm, Ovarian Cancer
- What is being tested?
- Doppler ultrasound
- How many people
- 100 participants
- Where
- 2 sitesTaiwan
- Study dates
- 19 Jan 2026to 31 Dec 2030
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Women with cervical cancer, cervical intraepithelial neoplasm, ovarian cancer, and the disease-free control
Who may be able to join
- Regarding the topic "Hemoperfusion characteristics of cervical cancer and precancerous lesions, and the correlation between hemoperfusion and prognosis":
- Adult women who have had a normal cervical smear within the past three years and have no other gynecological cancers (control group).
- Adult women with cervical cancer or precancerous lesions.
- Regarding the topic "Correlation between hemoperfusion and prognosis of ovarian cancer":
- Adult women suspected of having ovarian cancer, fallopian tube cancer, or peritoneal cancer before surgery.
Who cannot join
- Regarding the topic "Hemoperfusion characteristics of cervical cancer and precancerous lesions of the cervix, and the correlation between hemoperfusion and prognosis":
- 1. Patients who cannot cooperate with vaginal 3D ultrasound scans.
- Regarding the topic "Correlation between hemoperfusion and prognosis of ovarian cancer":
- Patients who cannot cooperate with vaginal or abdominal 3D ultrasound scans.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan2 sites
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital,
New Taipei City, Banqiao, 22050
Sheng-Mou Hsiao, MD, +886-2-89667000 ext. 1818, smhsiao2@gmail.com
Far Eastern Memorial Hospital
New Taipei City, 220
Sheng-Mou Hsiao, MD, +886-2-89667000 ext. 1818, smhsiao2@gmail.com
About this study
This study will elucidate the role of 3D transvaginal ultrasound in assessing (1) cervical vascularity and blood flow in patients with cervical cancer and cervical intraepithelial neoplasm, and (2) tumor vascularity and blood flow in patients with ovarian cancer.
Read the detailed description
Patients and methods:
Women with cervical cancer, cervical intraepithelial neoplasm, ovarian cancer, or the control will be invited to particilate in this study.Then, 3D power Doppler Ultrasound will be performed to capture (1) the cervical volume, vascularity and blood perfusion, and (2) ovarian tumor vascularity and blood perfusion. The sonographic data will be correlated to clinical and pathological data.
- Being tested
- Doppler ultrasound
- Keywords
- 3D power Doppler sonography, cervical vascularization and blood flow
- Medical subject headings
- Uterine Cervical Neoplasms, Uterine Cervical Dysplasia, Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Doppler ultrasoundDiagnostic test
3D doppler ultrasound to measure VI, FI, VFI.
| Study group | Role | What they receive |
|---|---|---|
| cervical cancer | cervical cancer patients Receives: Diagnostic Test: Doppler ultrasound | |
| cervical intraepithelial neoplasm | cervical intraepithelial neoplasm patients Receives: Diagnostic Test: Doppler ultrasound | |
| control | Gynecological patients without cervical disease Receives: Diagnostic Test: Doppler ultrasound | |
| ovarian cancer | ovarian cancer patients Receives: Diagnostic Test: Doppler ultrasound |
What is being measured
The primary outcome is the main question the study is designed to answer.
Vascularization-flow index
- Compare the vascularization-flow index values between cervical cancer, cervical intraepithelial neoplasia and the control group.
- To assess whether vascularization-flow index is a predictor of progression-free survival in women with ovarian cancer
Measured: 3 years
Secondary outcomes (2)
Vascularization index
- Compare the vascularization index values between cervical cancer, cervical intraepithelial neoplasia and the control group. 2. To assess whether vascularization index is a predictor of progression-free survival in women with ovarian cancer
Measured: 3 years
Flow index
- Compare the flow index values between cervical cancer, cervical intraepithelial neoplasia and the control group. 2. To assess whether flow index is a predictor of progression-free survival in women with ovarian cancer
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2026
- Study start19 Jan 2026 (estimated)
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Far Eastern Memorial Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sheng-Mou Hsiao, MD, Far Eastern Memorial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07385976
- Sponsor's protocol ID
- 114237-F
- Status last verified
- Jan 2026
- First submitted
- 13 Jan 2026
- Last updated
- 4 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients
- ClinicalTrials.gov ID
- NCT07385976
- Acronym / sponsor ID
- 114237-F
- Keywords
- 3D power Doppler sonography, cervical vascularization and blood flow
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Far Eastern Memorial HospitalUniversity, hospital or other
- Study start
- 19 Jan 2026 (estimated)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 4 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will elucidate the role of 3D transvaginal ultrasound in assessing (1) cervical vascularity and blood flow in patients with cervical cancer and cervical intraepithelial neoplasm, and (2) tumor vascularity and blood flow in patients with ovarian cancer.
Detailed description
Patients and methods:
Women with cervical cancer, cervical intraepithelial neoplasm, ovarian cancer, or the control will be invited to particilate in this study.Then, 3D power Doppler Ultrasound will be performed to capture (1) the cervical volume, vascularity and blood perfusion, and (2) ovarian tumor vascularity and blood perfusion. The sonographic data will be correlated to clinical and pathological data.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 3 Months
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| cervical cancer | – | Diagnostic Test: Doppler ultrasoundcervical cancer patients |
| cervical intraepithelial neoplasm | – | Diagnostic Test: Doppler ultrasoundcervical intraepithelial neoplasm patients |
| control | – | Diagnostic Test: Doppler ultrasoundGynecological patients without cervical disease |
| ovarian cancer | – | Diagnostic Test: Doppler ultrasoundovarian cancer patients |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Women with cervical cancer, cervical intraepithelial neoplasm, ovarian cancer, and the disease-free control
Key inclusion criteria (5 listed)
- Regarding the topic "Hemoperfusion characteristics of cervical cancer and precancerous lesions, and the correlation between hemoperfusion and prognosis":
- Regarding the topic "Correlation between hemoperfusion and prognosis of ovarian cancer":
Key exclusion criteria (4 listed)
- Regarding the topic "Hemoperfusion characteristics of cervical cancer and precancerous lesions of the cervix, and the correlation between hemoperfusion and prognosis":
- 1. Patients who cannot cooperate with vaginal 3D ultrasound scans.
- Regarding the topic "Correlation between hemoperfusion and prognosis of ovarian cancer":
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Doppler ultrasound3D doppler ultrasound to measure VI, FI, VFI. | Diagnostic test | cervical cancer, cervical intraepithelial neoplasm, control, ovarian cancer |
Primary outcome
Vascularization-flow index
Time frame: 3 years
1. Compare the vascularization-flow index values between cervical cancer, cervical intraepithelial neoplasia and the control group. 2. To assess whether vascularization-flow index is a predictor of progression-free survival in women with ovarian cancer
2 secondary outcomes
Vascularization index
Time frame: 3 years
Flow index
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Cervical Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Head & Neck Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital,
New Taipei City, Taiwan
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cervical Cancer and Cervical Intraepithelial Neoplasm, run by Far Eastern Memorial Hospital at 2 sites in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 4 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Vascularization-flow index (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2026.